Lilly's retatrutide shows double Ozempic's weight loss in trial: what it means for Canadian PCOS and diabetes patients

This article is for informational purposes only and is not medical advice. Consult your Canadian healthcare provider about your situation.

A phase 3 trial reported by Reuters on October 28, 2026 found that retatrutide, Eli Lilly's investigational triple-receptor agonist, produced approximately double the weight loss of semaglutide (sold in Canada as Ozempic for type 2 diabetes and Wegovy for chronic weight management) in adults with type 2 diabetes, while also delivering superior blood-sugar control. The trial results, covered by CTV News, add to a growing body of evidence that next-generation incretin-based therapies may substantially outperform the GLP-1 drugs that Canadian patients currently access. For a hormone-care patient in Canada, the immediate takeaway is straightforward: retatrutide is not approved by Health Canada, is not available at any Canadian pharmacy, and has no provincial drug-plan listing. Patients with PCOS, type 2 diabetes, or obesity who are interested in this class of drug should continue working with their prescriber on currently approved options while this one moves through the regulatory pipeline.

What this means in Canada

Retatrutide is a GIP, GLP-1, and glucagon triple-receptor agonist, meaning it activates three separate hormonal pathways simultaneously. That distinguishes it from semaglutide, which targets only GLP-1 receptors, and from tirzepatide (sold in Canada as Mounjaro for type 2 diabetes and Zepbound for weight management), which targets GIP and GLP-1. Health Canada approved tirzepatide under the brand name Mounjaro in 2023 and Zepbound in 2024, so a dual agonist is already on the Canadian market. Retatrutide, the triple agonist, has received FDA Breakthrough Therapy designation in the United States but has not been submitted to Health Canada for review as of October 2026, and Health Canada has not issued any guidance on it.

On the coverage side, the picture for existing GLP-1 and dual-agonist drugs in Canada is already uneven. Ozempic is listed on most provincial formularies for type 2 diabetes, including Ontario's OHIP-linked Ontario Drug Benefit (ODB) program, Quebec's RAMQ, British Columbia's PharmaCare, and Alberta's AHCIP, though prior-authorization criteria apply. Wegovy, the higher-dose semaglutide approved for weight management, has much spottier coverage: most provincial plans do not fund it for obesity alone, and patients often pay out of pocket, with costs running roughly CAD $350 to $500 per month. Mounjaro's coverage for type 2 diabetes is expanding but remains inconsistent across provinces. Any future retatrutide listing would almost certainly follow the same slow provincial-formulary process, likely taking several years after a Health Canada approval. The SOGC (Society of Obstetricians and Gynaecologists of Canada) has not issued a position statement on retatrutide specifically, though the SOGC has previously acknowledged GLP-1 receptor agonists as an emerging option in PCOS management where insulin resistance is a factor.

What changed

The trial compared retatrutide directly against semaglutide in a population with type 2 diabetes, which is a harder test than placebo-controlled studies. Participants on retatrutide lost roughly twice the percentage of body weight over the trial period and reached lower HbA1c targets, the standard measure of long-term blood-sugar control. Earlier phase 2 data published in the New England Journal of Medicine in 2023 had already shown retatrutide producing weight loss of up to 24 percent of body weight in people with obesity but without diabetes, a figure that exceeded anything seen with semaglutide or tirzepatide at the time. The new phase 3 data in a diabetic population reinforces that signal and moves the drug closer to regulatory submission.

The mechanism matters for hormone-care patients specifically. Glucagon receptor activation, the third pathway retatrutide adds on top of GIP and GLP-1, appears to increase energy expenditure rather than just reducing appetite. For people with PCOS, where insulin resistance and weight gain are tightly linked to androgen excess and menstrual irregularity, a drug that works through multiple metabolic pathways could theoretically offer more benefit than a single-pathway agent. That hypothesis has not been tested in a PCOS-specific trial for retatrutide, and the SOGC has not commented on it.

What Canadian patients should know

If you have type 2 diabetes and are not at your weight or blood-sugar target on your current regimen, the drugs available to you in Canada right now include semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound). Your prescriber can assess whether you meet the criteria for provincial coverage. In Ontario, the ODB program covers Ozempic for type 2 diabetes with a confirmed diagnosis and a prescriber attestation; Wegovy is not covered for most patients. In Quebec, RAMQ covers semaglutide for diabetes under specific conditions. In BC, PharmaCare Plan W covers some GLP-1 agents for eligible low-income patients. Alberta's AHCIP covers Ozempic for diabetes but not Wegovy for obesity. These rules change, so confirm current status with your pharmacist or prescriber.

For PCOS patients, GLP-1 agents are not formally approved in Canada for PCOS itself. They are sometimes prescribed off-label where insulin resistance and weight are significant factors, and some Canadian telehealth platforms, including Cleo (a Canadian women's-health platform) and Science & Humans (scienceandhumans.com), facilitate access to these medications through licensed Canadian prescribers. Felix, a Canadian online pharmacy and prescribing service, also lists semaglutide among its offerings. None of these platforms can prescribe retatrutide, because it does not exist as an approved Canadian drug.

US-only platforms such as Midi Health, Hone Health, and Winona do not serve Canadian patients and cannot legally prescribe into Canada.

Limitations and open questions

Several things are genuinely unknown at this point. The full phase 3 dataset for retatrutide has not been published in a peer-reviewed journal as of this writing; the results reported by Reuters are from a trial readout, not a final publication. The long-term cardiovascular outcomes data, the kind that drove broader adoption of semaglutide after the SUSTAIN and SELECT trials, do not yet exist for retatrutide. The Endocrine Society and the American Diabetes Association have not yet updated their guidelines to incorporate retatrutide, and the SOGC has not addressed it.

The safety profile at higher doses also needs more scrutiny. Phase 2 data showed gastrointestinal side effects consistent with the GLP-1 drug class, including nausea and vomiting, but the glucagon agonism adds a theoretical risk of increased heart rate and blood pressure that will need to be characterized in larger populations over longer periods. Health Canada will require its own review of the full clinical package before any Canadian approval, a process that typically takes 12 to 18 months after submission, and no submission has been announced.

Finally, even if retatrutide clears Health Canada, the coverage question is separate. Provincial drug plans move slowly, and a drug that costs more than existing agents faces a high bar at the Canadian Drug Agency's (CDA-AMC) health technology assessment process before provinces will list it. Patients who saw Wegovy approved in Canada in 2021 and still cannot get it covered in most provinces in 2026 will recognize that pattern.

This article is for informational purposes only and is not medical advice. Consult your Canadian healthcare provider about your situation.

Editorial note

Hormone Journal articles are written by our editorial team and reviewed against published clinical guidelines, with a focus on Canadian patient access. We do not promote specific clinics or providers.